Effects of Inspiratory Muscle Training in Patients With Post COVID-19

Sponsor
Gazi University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05231395
Collaborator
(none)
30
1
2
35.7
0.8

Study Details

Study Description

Brief Summary

Coronavirus-2019 (COVID-19) is a new virus that emerged in December 2019 and spread quickly all over the world. Problems such as hypoxia, dyspnea, increased fatigue, decreased exercise capacity and respiratory muscle strength occur in COVID-19 patients.In addition, abnormalities in skeletal muscles due to systemic inflammation, mechanical ventilation, sedation and prolonged bed rest in hospital and intensive care patients cause decreased exercise capacity.

Condition or Disease Intervention/Treatment Phase
  • Other: Inspiratory Muscle Training Group
  • Other: Control Group
N/A

Detailed Description

Dyspnea is one of the most common long-term symptoms in COVID-19 patients. It has been determined that dyspnea that persists three and six months after hospital discharge is associated with peak oxygen consumption in hospitalized and discharged COVID-19 patients, while peak oxygen consumption decreases in patients with dyspnea. Inspiratory muscle training may be an effective treatment modality in the treatment of dyspnea in patients with dyspnea after COVID-19. The effects of inspiratory muscle training have been investigated in different lung diseases. In these studies, inspiratory muscle training increased respiratory muscle strength and endurance, exercise capacity, and quality of life, and decreased fatigue and dyspnea.

The aim of this study is to investigate the effects of inspiratory muscle training on oxygen consumption, muscle oxygenation, physical activity level, respiratory muscle strength and endurance, peripheral muscle strength, functional exercise capacity, dyspnea, fatigue and quality of life in patients with COVID-19.

Primary outcome measurement will be oxygen consumption (cardiopulmonary exercise test).

Secondary outcome will be muscle oxygenation (Moxy device), physical activity level (multi sensor activity device), pulmonary function (spirometer), functional exercise capacity (six-minute walk test), respiratory (mouth pressure device) and peripheral muscle (hand-held dynamometer) strength, inspiratory muscle endurance (incremental threshold loading test), functional status (Post-COVID-19 Functional Status Scale), dyspnea (London Chest Daily Living Activity Scale), fatigue (Fatigue Severity Scale) and quality of life (Saint George Respiratory Questionnaire).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Parallel AssignmentParallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Triple-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times. Evaluations and interventions will be performed different physiotherapist. In addition, before statistical analysis patients' groups will be coded.
Primary Purpose:
Supportive Care
Official Title:
Effects of Inspiratory Muscle Training on Oxygen Consumption Muscle Oxygenation and Physical Activity Level in Patients With Post-COVID-19
Actual Study Start Date :
Feb 25, 2022
Anticipated Primary Completion Date :
Jan 15, 2024
Anticipated Study Completion Date :
Feb 15, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Inspiratory Muscle Training Group

Patients in the training group will be performed inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.

Other: Inspiratory Muscle Training Group
Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure. Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks. Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week.

Sham Comparator: Control Group

Control group will be given breathing exercises as a home program for 8 weeks.

Other: Control Group
Control group will be given breathing exercises 120 times/day, 7days/week, for 8 weeks as home program. Control group will be followed-up by telephone once a week

Outcome Measures

Primary Outcome Measures

  1. Oxygen Consumption [First Day]

    Cardiopulmonary Exercises Test

Secondary Outcome Measures

  1. Respiratory Muscle Strength [Second day]

    Maximal inspiratory (MIP) and maximal expiratory (MEP) pressures expressing respiratory muscle strength were measured using a portable mouth pressure measuring device according to American Thoracic Society and European Respiratory Society criteria.

  2. Respiratory Muscle Endurance [Second day]

    Incremental threshold loading test

  3. Peripheral Muscle Strength [Second day]

    Hand held dynamometer

  4. Functional exercise capacity [Second day]

    6 minute walking test

  5. Fatigue Severity [First day]

    Fatigue Severity Scale (Turkish version) - Fatigue Severity Scale (FSS) is a self-reported questionnaire. FSS evaluates patient's fatigue severity. This questionnaire includes 9 items and score range for each item from 1 to 7 point (7-point Likert scale). Fatigue Severity Scale score is calculates by deriving an arithmetic mean. Cut-scores of over 4 are indicative of significant fatigue (higher scores show more severe fatigue).

  6. Respiratory Associated Quality of Life (respiratory) [First day]

    St. George Respiratory Questionnaire (Turkish version) (respiratory) - St. George Respiratory Questionnaire (SGRQ) is a self-reported questionnaire. SGRQ evaluates patients' respiratory disease associated quality of life. This questionnaire includes 2 part (part one is about symptoms (one subsection) and part two is about activity (seven subsection)) and 50 items. Some items scored as Likert scale and others scored as dichotomous (true/false).

  7. Dyspnea [First Time]

    London Chest Activity of Daily Living scale (LCADL): LCADL evaluates the limitation to perform activities of daily living by dyspnea and looks at four domains: selfcare, domestic, physical and leisure. It is composed of 15 items, which are scored by the patient as follows: 0 (I do not perform this activity because I never had to do it or it is irrelevant), 1 (I do not feel any breathless when performing this activity), 2 (I feel moderate breathless when performing this activity), 3 (I feel a lot of breathless in doing this activity), 4 (I cannot perform this activity due to breathless and I have no one who can do the activity for me) or 5 (I cannot perform this activity anymore and I need someone to do it for me or help me because of breathless).

  8. Muscle oxygenation [First and second day]

    Moxy® monitor

  9. Physical Activity Level [Second Day]

    Multi sensor activity monitor

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Between the ages of 18-75

  • Diagnosed with COVID-19

  • COVID-19 Polymerase Chain Reaction (PCR) test result negative

  • Volunteer to participate in the study

Exclusion Criteria:
  • Body mass index >35 kg/m2

  • Acute pulmonary exacerbation, acute upper or lower respiratory tract infection

  • Aortic stenosis, complex arrhythmia, aortic aneurysm

  • Serious neurological, neuromuscular, orthopedic, other systemic diseases or other diseases affecting physical functions

  • Cognitive impairment that causes difficulty in understanding and following exercise test instructions

  • Participated in a planned exercise program in the last three months

  • Bulla formation in the lung

  • Uncontrolled hypertension and/or diabetes mellitus, heart failure and cardiovascular disease

  • Contraindication for exercise testing and/or exercise training according to the American College of Sports Medicine

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Cardiopulmonary Rehabilitation Clinic Ankara Turkey 06560

Sponsors and Collaborators

  • Gazi University

Investigators

  • Principal Investigator: Başak KAVALCI KOL, Pt. MSc., Gazi University
  • Principal Investigator: Ece BAYTOK, Pt. MSc., Gazi University
  • Principal Investigator: Nilgün YILMAZ DEMİRCİ, Assoc.Prof, Gazi University
  • Study Director: Meral BOŞNAK GÜÇLÜ, Prof. Dr., Gazi University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Meral Boşnak Güçlü, Study director, PT, PhD, Prof.Dr. Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Head of Cardiopulmonary Rehabilitation Clinic, Gazi University
ClinicalTrials.gov Identifier:
NCT05231395
Other Study ID Numbers:
  • Gazi University-
First Posted:
Feb 9, 2022
Last Update Posted:
Mar 9, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Meral Boşnak Güçlü, Study director, PT, PhD, Prof.Dr. Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Head of Cardiopulmonary Rehabilitation Clinic, Gazi University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 9, 2022